EGFR and head and neck squamous cell carcinoma: It has also been reported to synergistically inhibit the growth of HNSCC cells via inhibition of the NF-κB signaling pathway when used in conjunction with erlotinib, a tyrosine kinase inhibitor of EGFR, which is frequently overexpressed in HNSCC cells [205].